Overview

Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is poised to register a CAGR of 5.1% during the forecast period 2022 to 2028.

The first immunisation given to infants is often the DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccine at two months of age. The capital "D" and "P" in DTaP refer to the higher amounts of Diphtheria and Pertussis antigens compared to Tdap products. Three contagious human diseases—diphtheria, tetanus, and pertussis—are prevented by the diphtheria, pertussis, and tetanus (DPT) vaccination. To generate acquired immunity against Diphtheria, Pertussis, and Tetanus, these vaccines are administered either during childhood or during middle life. DTP, also known as diphtheria, tetanus, and pertussis, are severe illnesses brought on by the bacteria. Diphtheria, tetanus, and pertussis vaccines are combined and administered intramuscularly as the DTP vaccine. In order to successfully immunise children up to the age of seven against Diphtheria, Tetanus, and Pertussis (whooping cough), diphtheria and tetanus toxoids and the pertussis vaccine are advised concurrently. This trend has primarily been caused by an increase in demand for combination vaccinations that are tetravalent and then pentavalent. The funding provided by GAVI (Global Alliance for Vaccines and Immunizations) for further DTP-containing vaccines has played a significant role in driving the rising demand for combination products. The pertussis vaccine market is expected to increase rapidly due to the high birth rate and rising demand for the vaccine, which will favourably affect the worldwide Diphtheria, Pertussis and Tetanus (DTP) Vaccine market. Other factors anticipated to contribute to market expansion include a rise in the frequency of DPT cases, improvements in vaccine administration systems, the creation of technologically sophisticated vaccines, and government initiatives

FutureWise Market Research has instantiated a report that provides an intricate analysis of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market:
• AJ Vaccines
• Bionet-Asia
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Massbiologics
• Meiji Holdings Co., Ltd. (KM biologics Co., Ltd.)
• Merck & Co., Inc
• Panacea Biotec Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd.
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Segmentation:
By Product Type
• DTaP Vaccine
• TD Vaccine
• Tdap Vaccine

By Age Group  
• Adult
• Pediatrics

By End User
• Hospitals
• Clinics
• Vaccination Centers

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market By Product Type, By Age Group, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. DTaP Vaccines
   7.2. TD Vaccines
   7.3. Tdap Vaccines

8. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Age Group Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Adult
   8.2. Pediatric

9. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospitals
   9.2. Clinics
   9.3. Vaccination Centers

10. North America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. AJ Vaccines
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Bionet-Asia
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. GlaxoSmithKline plc (GSK)
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Johnson & Johnson
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Massbiologics
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Merck & Co., Inc.
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Panacea Biotec Ltd.
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Sanofi
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Serum Institute of India Pvt. Ltd.
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures